Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: A MASTER DAPT trial sub-Analysis

Keyphrases

• Acute Coronary Syndrome 16%
• Adverse Cardiac Events 8%
• All-cause Mortality 16%
• Biodegradable Polymer Sirolimus-eluting Stent 8%
• Bleeding 8%
• Bleeding Academic Research Consortium 33%
• Bleeding Events 8%
• Bleeding Rate 8%
• Cerebral Events 8%
• Clinical Trial Registry 8%
• Co-primary 8%
• Complex Percutaneous Coronary Intervention 100%
• Confidence Interval 50%
• Coronary Patients 8%
• Dual Antiplatelet Therapy 100%
• Duration of Antiplatelet Therapy 100%
• Hazard Ratio 50%
• High Bleeding Risk 100%
• High Bleeding Risk Patients 16%
• Intervention Complexity 8%
• MACCE 33%
• Medical Complexity 8%
• Myocardial Infarction 16%
• Net Adverse Clinical Events 16%
• Percutaneous Coronary Intervention 16%
• Recurrent Ischemic Events 8%
• Therapy Discontinuation 8%

Medicine and Dentistry

• Acute Coronary Syndrome 15%
• Antiplatelet 100%
• Apoplexy 15%
• Bleeding 100%
• Cause of Death 15%
• Clinical Trial 7%
• Hazard Ratio 46%
• Myocardial Infarction 15%
• Nonaqueous Capillary Electrophoresis 23%
• Percutaneous Coronary Intervention 100%
• Rapamycin 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Acute Coronary Syndrome 15%
• Antiplatelet 100%
• Bleeding 100%
• Cause of Death 15%
• Clinical Trial 7%
• Heart Infarction 15%
• Rapamycin 7%